Clinical Trial Update: Study Exploring Safety, Pharmacokinetic and Pharmacodynamic of BN82451 in Male Huntington's Disease Patients [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the safety, pharmacokinetics, and pharmacodynamics of BN82451 in males with Huntington's disease was terminated; results were posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Huntington Disease

Drugs mentioned

• BN82451

Snippet

Sponsor: Ipsen | Conditions: Huntington's Disease | Phase 2 | Status: TERMINATED | Results posted: 2018-01-29